Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria

Boyanova, Lyudmila

doi:10.1099/jmm.0.009993-0

Cited by 49 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five H. pylori strains were resistant to AMX, MNZ and CLR, two of them exhibiting quadruple resistance. Resistance to four of the five antibacterials tested was found in 0.7% of the untreated and 1.8% of the treated adults [26]. Quadruple resistance of H. pylori has not been reported in Europe and the USA in last 5 years, although a study from India reported this type of resistance in 2.6% of isolates [27].…”

Section: Discussionmentioning

confidence: 93%

Antibiotic resistance of Helicobacter pylori in Mongolia

Bolor-Erdene

Namdag

Yamaoka

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction.The resistance of Helicobacter pylori to recently available antibiotic treatment regimens has been recognized as a growing problem. Therefore, the aim of this study was to determine the prevalence of antibiotic resistance among H. pylori strains isolated from Mongolians. Methodology. All gastric biopsy specimens were obtained during upper gastrointestinal endoscopy from patients referred for the exploration of dyspepsia. The urease positive samples by rapid urease test were cultured according to standard microbiological procedures and H. pylori were grown under microaerophilic conditions on selective Pylori agar. H. pylori antibiotic sensitivity was examined using E-test. In addition, the mutations of the corresponding gene were studied by GenoType HelicoDR DNA strip testing. Results. Three hundred twenty patients, 216 female and 104 male in the ages range of 18 to 83 years were included in this study. Rapid urease test yielded positive results for 65.9% (211/320). Among them, we have successfully obtained 72% H. pylori isolates. The antibiotic resistance rates were 35.5% for clarithromycin, 68.4% metronidazole, 23.0% amoxicillin, 25.0% tetracycline, 28.2% erythromycin and 14.5% nitrofuranton. Resistance for 2 drugs was 34.5% and that of 3 drugs was observed in 14.5% of isolates. The most prevalent mutation was A2147G followed by A2146G and D91Y. The prevalence of H. pylori infection increased among Mongolian population and the prevalence of resistance of H. pylori is very high to metronidazole, and moderate to clarithromycin. Conclusion. The data on antimicrobial susceptibilities provided by the present study is may assist the clinicians on the effectiveness of treatment regimens.

show abstract

Section: Discussionmentioning

confidence: 93%

Antibiotic resistance of Helicobacter pylori in Mongolia

Bolor-Erdene

Namdag

Yamaoka

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…In a region with high rates of clarithromycin resistance, sequential or concomitant therapy is recommended as the first-line H. pylori eradication treatment [25] . The primary reason for the growth in antibiotic resistance is the emergence of point mutations in the H. pylori genome [26] . Thus, the development of novel treatment methods to increase eradication rates and reduce antibiotic resistance is needed.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

“…In areas with high rates of clarithromycin resistance, the first option is a sequential or concomitant regimen [6] . The main reason for the increase in antibiotic resistance is the accumulation of point mutations in the H. pylori DNA, which are in most cases associated with the overuse of antibiotics [7] . Therefore, the development of a new treatment regimen that not only improves the eradication rate but also reduces the frequency of adverse effects remains the principal challenge.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of the efficacy of probiotics inHelicobacter pylorieradication therapy

Zhu¹,

Chen²,

Zheng³

et al. 2014

WJG

View full text Add to dashboard Cite

AIM:To evaluate the role of probiotics in the standard triple Helicobacter pylori therapy. METHODS:In this meta-analysis, we investigated the efficacy of probiotics in a standard triple H. pylori therapy in adults. Searches were mainly conducted in MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Fourteen studies met our criteria, and the quality of these studies was assessed using the Jadad scale. We used STATA version 12.0 to extract data and to calculate the odds ratios (ORs), which are presented with the corresponding 95% confidence intervals (CIs). The data are presented as forest plots. RESULTS:The pooled ORs for the eradication rates calculated by intention-to-treat analysis and perprotocol analysis in the probiotic group vs the control group were 1.67 (95%CI: 1.38-2.02) and 1.68 (95%CI: 1.35-2.08), respectively, using the fixed-effects model. The sensitivity of the Asian studies was greater than that of the Caucasian studies (Asian: OR = 1.78, 95%CI: 1.40-2.26; Caucasian: OR = 1.48, 95%CI: 1.06-2.05). The pooled OR for the incidence of total adverse effects was significantly lower in the probiotic group (OR = 0.49, 95%CI: 0.26-0.94), using the random effects model, with significant heterogeneity (I 2 = 85.7%). The incidence of diarrhea was significantly reduced in the probiotic group (OR = 0.21, 95%CI: 0.06-0.74), whereas the incidence of taste disorders, metallic taste, vomiting, nausea, and epigastric pain did not differ significantly between the probiotic group and the control group. CONCLUSION:Supplementary probiotic preparations during standard triple H. pylori therapy may improve the eradication rate, particularly in Asian patients, and the incidence of total adverse effects. and rational search strategy, inclusion criteria, and statistical analyses, we found that supplementary probiotic preparations given during standard triple H. pylori therapy conferred a higher eradication rate, particularly in Asian patients, and a lower incidence of total adverse effects, particularly diarrhea. META-ANALYSIS

show abstract

Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria

Cited by 49 publications

References 32 publications

Antibiotic resistance of Helicobacter pylori in Mongolia

Antibiotic resistance of Helicobacter pylori in Mongolia

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Meta-analysis of the efficacy of probiotics inHelicobacter pylorieradication therapy

Contact Info

Product

Resources

About